Bioventus Inc.
BVS
Rank in Stocks
#10060
Bioventus Inc., a medical device company, focuses on relieving pain and... Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Share Price
$10.99
Last synced: 2026-11-11
Market Cap
$751.46M
Change (1 day)
-1.70%
Change (1 year)
45.18%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Bioventus Inc. (BVS)
Category
Healthcare
Dividend yield history for Bioventus Inc. (BVS)
Bioventus Inc. (stock symbol: BVS) dividend yield (TTM) as of 2025: 0.00%
Average dividend yield, last 5 years : 0.01%
Average dividend yield, last 5 years : 0.01%
Dividend yield history for Bioventus Inc. (BVS) from 2013 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | 0.06% | -97.14% |
| 2020 | 2.10% | 150.00% |
| 2019 | 0.84% | 16.67% |
| 2018 | 0.72% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | 0.10% | -54.55% |
| 2014 | 0.22% | -4.35% |
| 2013 | 0.23% | 0.00% |
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 2.37% |
US
|
|
| 2.96% |
IE
|
|
| 1.21% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
US
|
Questions about Bioventus Inc.'s dividend yield
What was Bioventus Inc.'s dividend yield in 2025?
In 2025, Bioventus Inc.'s dividend yield was 0.00%, compared with 0.00% in 2024.
How has Bioventus Inc.'s dividend yield changed since 2020?
From 2020 to 2025, Bioventus Inc.'s dividend yield was highest in 2020 (2.10%) and lowest in 2025 (0.00%).
How does Bioventus Inc.'s dividend yield compare with similar companies?
Bioventus Inc.'s dividend yield (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is Medtronic plc, with 2.96%.